Profound Medical (PROF)

• Market cap: $121M
• 1 day: -5.39%
• 5 days: -16.18%
• 1 month: -15.13%
• 3 months: -39.70%
• 6 months: -49.56%
• Year to date: -48.86%
• 1 year: -50.79%
• 5 years: -66.80%
• 10 years: -59.11%
• Sector: Healthcare
• Industry: Medical Devices

About: Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Employees: 142

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

164% more call options, than puts

Call options by funds: $29K | Put options by funds: $11K

37% more capital invested

Capital invested by funds: $75M [Q3] → $103M (+$28.1M) [Q4]

18% more funds holding

Funds holding: 44 [Q3] → 52 (+8) [Q4]

7.4% more ownership

Funds ownership: 38.47% [Q3] → 45.86% (+7.4%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $11 172% upside
• Avg. target: $11 172% upside
• High target: $11 172% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Benjamin Haynor 0% 1-year accuracy 0 / 3 met price target

172% upside $11

Buy Maintained

23 Apr 2025